

Professor John Zalcborg reacts to the QINLOCK® (riporetinib) PBS listing



ST is delighted to announce that our therapy QINLOCK® (riporetinib) was reimbursed for eligible Australian GIST patients from December 1 2021. International GIST expert Professor John Zalcborg reacts to the listing. [Click for more.](#)